Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study

Abstract

In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for breakthrough pain (BTP) in adult opioid-tolerant cancer patients. Patients received one dose of placebo, SLF 100, 200 and 400 μg in random order at four pain episodes. The primary efficacy endpoint was pain intensity difference (PID) from baseline. Twenty-seven patients received study medication. Overall PID increased significantly with SLF 400 μg versus placebo (8.57 mm, p <0.0001). Improvements were statistically different from placebo at 15 min (p = 0.005). SLF 100 and 200 μg showed a numerical trend towards improved pain relief. A dose that gave a clinically important reduction in pain (PID > 20 mm) was identified by 95% of patients. Reduced use of rescue medication (p < 0.001, SLF 400 μg) and improved global assessment of treatment (p = 0.0146, SLF 400 μg) confirmed these differences as clinically important. Nausea and dizziness were the most common treatment-related adverse effects. SLF appears to be a fast, effective and well-tolerated treatment for BTP.

Keywords

cancer fentanyl opioid pain sublingual

Get full access to this article

View all access options for this article.

References

Svendsen KB , Andersen S. , Arnason S. , et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9: 195-206.

Davies AN Cancer-related breakthrough pain. Br J Hosp Med ( Lond) 2006; 67: 414-416.

Caraceni A. , Portenoy RK An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82: 263-274.

Goudas LC , Bloch R. , Gialeli-Goudas M. , et al. The epidemiology of cancer pain. Cancer Invest 2005; 23: 182-190.

Portenoy RK , Hagen NA Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281.

Portenoy RK , Hagen NA Breakthrough pain: definition and management. Oncology ( Williston Park) 1989; 3: 25-29.

Rhiner M. , Palos G. , Termini M. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate. Clin J Oncol Nurs 2004; 8: 507-512.

Roy SD , Flynn GL Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1988; 5: 580-586.

Coluzzi PH , Schwartzberg L. , Conroy JD , et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91: 123-130.

10.

Labroo RB , Paine MF , Thummel KE , Kharasch ED Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions . Drug Metab Dispos 1997; 25: 1072-1080.

11.

Ozdemir V. , Kalow W. , Tang BK , et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.

12.

Zhang H. , Zhang J. , Streisand JB Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications . Clin Pharmacokinet 2002; 41: 661-680.

13.

Shojaei AH Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15-30.

14.

Bredenberg S. , Duberg M. , Lennernas B. , et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003; 20: 327-334.

15.

Lennernas B. , Hedner T. , Holmberg M. , et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005; 59: 249-253.

16.

PSI Professional Standards Working Party. Guidelines for standard operating procedures for good statistical practice in clinical research. Statisticians in the pharmaceutical industry, version 6, 1 June 2000. http://www.psiweb.org/docs/gsop.pdf (last accessed July 2009 ).

17.

Farrar JT , Berlin JA , Strom BL Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003; 25: 406-411.